In June and July 2021, we conducted 25 interviews with 36 key measles stakeholders to better understand partner perspectives on the introduction of MR 5-dose. Interviewees included global, regional, and country-level counterparts from a range of organizations, including UNICEF, WHO, Gavi, U.S. CDC, and IFRC. The process revealed strong alignment on the value of using MR 5-dose as a tool for improving coverage and equity. But stakeholders noted: • A lack of prioritization • Absence of leadership • No agreed-upon global strategy • And the need for technical assistance, financial support, operational research, and better information sharing and communications Finally, interviewees saw near-term opportunities to advance the issue, citing COVID-19 response investments and activities as likely to minimize barriers to MR 5-dose introduction.